Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 10

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 10
---
 the relationship of certain of our pathologists 
 with existing customers.                                                     |

| ● | PPLS may be unable to maintain equipment or generate revenue when its equipment 
 is not operational.                                                             |

| ● | If our sole laboratory facility becomes damaged or inoperable, loses its                                                         
 accreditation, or is required to vacate the facility, PPLS’ ability to sell its products or provide diagnostic assays and pursue 
 its research and development efforts may be jeopardized.                                                                         |

| ● | Disruption in the commercial courier delivery services used by PPLS to transport 
 sputum samples could harm its business.                                          |

| ● | Security breaches, data loss, and other disruptions could compromise sensitive 
 information of PPLS’ business.                                                 |

| ● | If PPLS uses hazardous chemicals in a manner that causes injury, PPLS could 
 be liable for damages.                                                      |

| ● | If PPLS is unable to successfully scale its operations to support demand 
 its business could suffer.                                               |

| ● | PPLS must dedicate substantial time and resources to its complex billing 
 process to be paid.                                                      |

| ● | Delays of third-party billing and collection providers and an in-house billing 
 function to transmit claims to payors could have an adverse effect on PPLS.    |

| 3 |

Risks Related to Intellectual Property Rights

| ● | If we fail to comply with our obligations imposed by any intellectual property                                       
 licenses with third parties that we may need in the future, we could lose rights that are important to our business. |

| ● | We may need to obtain licenses of third-party technology that may not be 
 available to us or available to us on reasonable terms.                  |

| ● | Our competitive position depends on protection of our intellectual property. |

| ● | Diagnostic tests and therapeutic products we develop could be subject to 
 infringement claims.                                                     |

| ● | We may become involved in lawsuits to protect or enforce our intellectual 
 property.                                                                 |

| ● | If we are unable to protect our trade secrets, our business and competitive 
 position could be harmed.                                                   |

| ● | Changes in patent law could impair our ability to protect our tests and product 
 candidates.                                                                     |

| ● | Our patent protection could be reduced or eliminated for non-compliance with 
 governmental requirements.                                                   |

| ● | Patent terms may be inadequate to protect our diagnostic tests or therapeutic 
 product candidates.                                                           |

| ● | Issued patents could be found invalid or unen